Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Cash from Operations: 2009-2025

Historic Cash from Operations for Lifecore Biomedical (LFCR) over the last 17 years, with May 2025 value amounting to -$206,000.

  • Lifecore Biomedical's Cash from Operations fell 38.65% to $5.3 million in Q2 2025 from the same period last year, while for May 2025 it was -$206,000, marking a year-over-year decrease of 180.16%. This contributed to the annual value of -$206,000 for FY2025, which is 180.16% down from last year.
  • Per Lifecore Biomedical's latest filing, its Cash from Operations stood at -$206,000 for FY2025, which was down 180.16% from $257,000 recorded in FY2024.
  • Lifecore Biomedical's 5-year Cash from Operations high stood at $16.5 million for FY2021, and its period low was -$22.6 million during FY2022.
  • Its 3-year average for Cash from Operations is -$5.8 million, with a median of -$206,000 in 2025.
  • As far as peak fluctuations go, Lifecore Biomedical's Cash from Operations skyrocketed by 196.66% in 2021, and later crashed by 237.17% in 2022.
  • Over the past 5 years, Lifecore Biomedical's Cash from Operations (Yearly) stood at $16.5 million in 2021, then tumbled by 237.17% to -$22.6 million in 2022, then climbed by 22.80% to -$17.4 million in 2023, then skyrocketed by 101.47% to $257,000 in 2024, then plummeted by 180.16% to -$206,000 in 2025.